Vertex Pharmaceuticals to acquire Alpine Immune Sciences in $4.9 billion deal
Vertex Pharmaceuticals Incorporated (VRTX) has announced its plans to acquire Alpine Immune Sciences, Inc. (ALPN), a company dedicated to the discovery and development of novel protein-based immunotherapies. The acquisition, valued at approximately $4.9 billion, will see Vertex purchasing Alpine at $65 per share in an all-cash transaction. The strategic acquisition has received unanimous support from…